Abstract. The mechanisms underlying cervical cancer progression have not yet been fully elucidated; thus, further investigations are required. Chaperonin containing TCP1 subunit 3 (CCT3) expression was found to be upregulated in several types of human cancer. However, the roles of CCT3 in cervical cancer remain poorly understood. Thus, the present study aimed to determine the roles of CCT3 in the progression of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). For this purpose, the Tumor Immune Estimation Resource and Gene Expression Profiling Interactive Analysis databases were used to analyze the mRNA and protein expression levels of CCT3 in CESC samples. The effects of CCT3 on the proliferation and migration of CESC in vitro were determined using various experiments, including proliferation, Transwell and flow cytometric assays. The results revealed that CCT3 expression was significantly upregulated in CESC, which was associated with a poor prognosis. The silencing of CCT3 suppressed CESC cell proliferation, migration and invasiveness in vitro. Additionally, CCT3-knockdown promoted CESC cell apoptosis and cell cycle arrest, and suppressed fibronectin 1 (FN1) protein expression. Furthermore, rescue assays demonstrated that CCT3 promoted CESC proliferation and migration via FN1. In conclusion, the findings of the present study demonstrated that CCT3 is closely associated with the progression of CESC. Thus, CCT3 may be considered a novel, promising biomarker, and a possible therapeutic target for CESC.

Introduction

As indicated by global cancer statistics, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) ranks as the fourth most common cause of cancer-related mortality in women (1,2). On average, the 5-year survival rate of patients with CESC is 17% (3). Human papillomavirus (HPV) infection is considered the leading cause of CESC (4). However, it is suggested that other unknown mechanisms may be involved in CESC occurrence (4). It has been determined that inflammation plays an important role in tumor development (5). In addition to HPV infection, several other factors have been identified as crucial regulators of CESC progression, such as G-rich RNA sequence binding factor 1 and transmembrane emp24 domain-containing protein 5 (6). Thus far, the exact mechanisms underpinning CESC occurrence and progression remain elusive. Therefore, exploration of the mechanisms underlying the pathogenesis of CESC, and the development of novel treatment strategies, are essential.

Chaperone containing TCP1 (CCT) is a bicyclic chaperone complex comprising 8 unequal components (CCT1-CCT8) (7). CCT family members are of importance for actin and tubulin folding, which is necessary for cellular migration and cell cycle progression (8). Although CCT1 (9), CCT2 (10), CCT4 (11) and CCT8 (12) have been implicated in cellular proliferation, little is known of the function of CCT3 in tumorigenesis. Recent research in kidney cancer has identified CCT3 as a novel target and indicator of carcinoma, upstream of yes-associated protein and transcription factor CP2 (13). The expression of CCT3 was also found to be increased in hepatocellular carcinoma (HCC), which was associated with poor patient prognosis (14). In addition, CCT3 upregulation in thyroid papillary carcinoma (PTC) has been demonstrated to induce PTC cell proliferation, cell cycle arrest and apoptosis (15). In gastric cancer (GC), experimental CCT3-knockdown suppressed GC cellular proliferation and induced apoptosis. However, the exact role of CCT3 in the occurrence of CESC remains unclear.

The present study aimed to determine the correlation between CCT3 expression and CESC prognosis and the role of CCT3 in the progression of CESC. For this purpose, the Tumor Immune Estimation Resource and Gene Expression Profiling Interactive Analysis databases were used to analyze the mRNA and protein expression levels of CCT3 in CESC samples. The effects of CCT3 on the proliferation and migration of CESC...
were determined using various methods, including proliferation, Transwell and flow cytometric assays.

Materials and methods

Cell lines and culture. HeLa and SiHa cells were obtained from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. All cells were cultured in RPMI-1640 medium (HyClone; Cytiva) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) at 37°C (5% CO2).

Construction of lentivirus expression cassette and transfection. To generate the cellular knockdown model, CCT3 short hairpin RNA (shRNA; 5'-GCTGTGAAGCTGCTACATG-3') and shRNA negative control (shCtrl; 5'-TTCTCCGAACGTGTTAAGT-3') were designed by Shanghai GeneChem Co., Ltd. A lentivirus expression cassette expressing CCT3 shRNA was cloned as described in a previous study (16). Briefly, after annealing, shRNA fragments were integrated into a lentiviral GV493 vector (huU6-MCS-CBh-GFP-IRE-puromycin; Shanghai GeneChem Co., Ltd.). To generate the overexpression model, the CCT3 and FN1 coding sequences were synthesized by Shanghai GeneChem Co., Ltd. and integrated into lentiviral GV492 (Ubi-MCS-3FLAG-CBh-gcGFP-IRE-puromycin). The empty GV492 vector was used as a negative control (OECtrl). A total of 4x10^5 293FT cells per well were seeded into a 6 well plate, and transduced with the target gene construct and the envelope, packaging and recombinant lentiviral plasmids (3rd generation system; Cyagen Biosciences, Inc.) at 37°C. After 48 h, the cells were centrifuged at 10,000 x g for 4 h (4°C) and the virus-containing supernatant was harvested. HeLa and SiHa cells at the 3rd passage were then infected (multiplicity of infection, 50) using 5 µg/ml Polybrene. The cells were cultured at 37°C for 3 days in RPMI-1640 medium containing 10% FBS and 1 µg/ml puromycin (in order to select puromycin-resistant cells) and 0.25 µg/ml puromycin was used for maintenance. Similarly, HeLa and SiHa cells transfected with blank lentivirus were used to generate the controls (shCtrl and OECtrl). After 2 days, reverse transcription-quantitative PCR (RT-qPCR) was performed to confirm target gene expression. All transfections were conducted using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed into cDNA using the RevertAid First Strand cDNA Synthesis kit (Promega Corporation) following the manufacturer's instructions. qPCR was subsequently performed using SYBR® Green Supermix (Bio-Rad Laboratories, Inc.) as previously described (16,17). The qPCR reaction conditions were as follows: Initial denaturation at 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec, 60°C for 10 sec and 72°C for 30 sec. The specific primers were as follows: CCT3 forward, 5'-TCAGTGGTGTCATCTTTGG-3' and reverse, 5'-CCTCCAGGTATTTTCTTCACTCT-3'; and GAPDH forward, 5'-TGAAGTCACGGACAGGACC-3' and reverse, 5'-CACAGCGGTGCAGACCCAA-3'. Relative expression levels were calculated using the 2^△△Cq method (18).

Cell viability assay. Cell viability was determined using an MTT assay. HeLa and SiHa cells infected with CCT3 shRNA lentivirus and/or FN1 overexpression lentivirus were seeded into 96-well plates (2x10^3 cells/well) and incubated at 37°C for 5 days. Following incubation, MTT (Sigma-Aldrich; Merck KGaA) solution was added to each well, followed by incubation for a further 4 h. The MTT solution was then aspirated and 100 µl DMSO (Sigma-Aldrich; Merck KGaA) was added to dissolve the formazan crystals. The number of viable cells was counted using an automated microplate reader ( Molecular Devices, LLC) at a wavelength of 570 nm.

Celigo® adherent cell cytometry system. HeLa and SiHa cells infected with CCT3 shRNA lentivirus and/or the FN1 overexpression lentivirus were harvested in the logarithmic growth phase (Gibco; Thermo Fisher Scientific, Inc.), resuspended in complete medium and seeded into 96-well plates (2x10^3 cells/well). After plating, a Celigo Image Cytometer (Nexcelom) was used to evaluate the number of cells by scanning for green fluorescence daily, for 5 days at room temperature.

Flow cytometric analysis. HeLa and SiHa cells were transfected with CCT3 shRNA or the associated negative control. An apoptosis assay was performed using the Annexin V-FITC/ propidium iodide (PI) Apoptosis Detection kit (Nanjing KeyGen Biotech Co., Ltd.) following the manufacturer's protocol. The cells were analyzed using a flow cytometer (FACSCalibur; BD Biosciences) and FlowJo V10.0 (BD Biosciences). Cells were also stained using a PI staining kit (Nanjing KeyGen Biotech Co., Ltd.) and the cell cycle was evaluated by flow cytometry as previously described (16).

Cellular migration and invasion assays. Cellular invasion and migration assays were conducted using 24-well Transwell plates with or without Matrigel, respectively (BD Biosciences). For the migration assay, transfected cells (1x10^5) were seeded into the upper chamber without Matrigel. For the invasion assay, transfected cells (1x10^5) were seeded in the upper Matrigel-coated chamber without serum; for both assay types, the lower chamber was filled with culture medium supplemented with 15% FBS as a chemoattractant and cultured for 48 h in 37°C. The migratory and invasive cells in the lower chamber were room temperature formalin-fixed for 30 min, stained with crystal violet at room temperature for 20 min and washed with PBS. Cells were counted by Olympus CX35 light microscope.

Western blot analysis. Cells were harvested using an enzymatic digestion method. Subsequently, ice-cold lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% EDTA and 0.5% NP-40) was added and cells were incubated for 20 min at 4°C. Centrifugation was performed at 13,000 x g at 4°C for 15 min. Total protein concentration was determined using a BCA Protein Quantification kit. Total protein (30 µg/lane) was separated via SDS-PAGE on a 10% gel and subsequently transferred to a PVDF membrane using the Bio-Rad Transfer System (Bio-Rad Laboratories, Inc.). Membranes were blocked with 5% non-fat dry milk for 1 h at room temperature and incubated with primary antibodies overnight at 4°C (Table SI). Following
secondary antibody incubation for 1 h at room temperature (HRP-conjugated anti-rabbit and anti-mouse; both 1:3,000; cat. nos. 7074 and 7076, respectively; Cell Signaling Technology, Inc.), protein expression was determined using the Pierce ECL System (Thermo Fisher Scientific, Inc.). The protein band density was determined using ImageJ (version 1.53; National Institutes of Health).

GSE46857, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46857 (20) and GSE9750, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9750 (21) datasets]. The associations between patient overall survival and disease-free survival, and CCT3 mRNA expression levels were analyzed using TIMER 2.0 and the GEPIA database. The protein expression level of CCT3 in cancer and normal tissues was analyzed using the Protein Atlas database (https://www.proteinatlas.org/).

Statistical analysis. All data are presented as the mean ± SD. Statistical differences between two groups were determined using the unpaired Student’s t-test, and one-way ANOVA with Tukey’s post hoc test was used to analyze the differences between multiple groups. P<0.05 was considered to indicate a statistically significant difference. Overall survival was assessed using the Kaplan-Meier method. The log-rank test was applied to determine significant differences. Correlation between CCT3 and FN1 was calculated using Spearman’s method. All statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc.).

Results
Evaluation of CCT3 expression level in GEO and The Cancer Genome Atlas (TCGA) datasets. To determine the role of
CCT3 in tumor progression, CCT3 mRNA expression was first measured in various tumors using the TIMER database. The data revealed that CCT3 expression was increased in multiple types of human cancer compared with healthy individuals (Fig. 1A). Additionally, the analysis of GEPIA datasets revealed that CCT3 expression was markedly increased in 50 paired CESC tumors (Fig. 1B). The upregulated expression of CCT3 in tumors was further confirmed in the GSE63514, GSE46857 and GSE9750 datasets (Fig. 1C-E). These results indicated that CCT3 may play a role in CESC.

Increased expression of CCT3 is associated with poor patient prognosis. The results of the present study further revealed that in the Protein Atlas database, CCT3 protein expression
was increased in CESC samples compared with normal samples (Fig. 2A). Furthermore, increased CCT3 expression was associated with a shorter overall survival rate, as indicated by Kaplan-Meier survival using the GEPIA database (Fig. 2B). The results also revealed that a higher expression level of CCT3 was associated with the poor disease-free survival of patients with CESC, as determined using data from the GEPIA database (Fig. 2C). These findings demonstrated that CCT3 may be a potential biomarker for CESC that may be involved in regulating cancer progression.

**CCT3-knockdown decreases cellular migration and invasion ability.** Next, HeLa and SiHa cells were established in which CCT3 expression was knocked down (Fig. 3). CCT3 mRNA and protein levels were then determined in the HeLa and SiHa cells transfected with CCT3 shRNA (Fig. 3A-D). The results of the Transwell assay indicated that the CCT3-knockdown inhibited the migration of HeLa and SiHa cells by ~90 and 70%, respectively (Fig. 3E and F). Subsequently, the effects of CCT3-knockdown on CESC cell invasiveness were evaluated. The results revealed that the invasiveness of HeLa and SiHa cells was decreased by ~90 and 45%, respectively, in the CCT3-knockdown groups compared with the control groups (Fig. 3G and H).

**CESC cell cycle progression is inhibited, and apoptosis is induced, following CCT3-knockdown.** Cellular proliferation analysis using Celigo (Fig. 4A and B) and MTT (Fig. 4C and D) assays demonstrated that CCT3-knockdown significantly inhibited the proliferation of both HeLa and SiHa cells. CCT3 has been reported to participate in cell cycle regulation (22). The present study data revealed that decreased expression of CCT3 increased the proportion of cells in the G2/M phase, but decreased the G0/G1 ratio in SiHa and HeLa cells (Fig. 5A and B, respectively). The results also revealed that SiHa and HeLa cells with knocked down CCT3 expression exhibited higher levels of apoptosis (Fig. 5C and D). Moreover, expression of the pro-apoptotic protein Bcl2 was inhibited following CCT3-knockdown, while anti-apoptotic Bax was upregulated in both SiHa and HeLa cells (Fig. 5E). However, a promotive effect of CCT3 overexpression in cellular proliferation, migration and invasiveness was not observed in HeLa or SiHa cells (Fig. 6A-F). However, these results still suggest that CCT3 promoted CESC cell proliferation, migration and invasiveness.
CCT3 affects the expression of multiple key cancer regulators in CESC. To evaluate the potential mechanisms of action of CCT3 in CESC, the expression levels of multiple proliferation, migration and cell cycle regulators [including cadherin (CDH)1, CDH2, phosphorylated (p)-p38, FN1, matrix metalloproteinase (MMP)2, Twist-related protein (TWIST), MMP9, Snail, mTOR, MYC, NF-κB-p65, p-mTOR, vimentin (VIM), p-NF-κB-p65, p-β-catenin, p38, β-catenin and Slug] were

Figure 5. CCT3-knockdown induces cell cycle arrest and apoptosis in CESC cells. CCT3 was inhibited by shRNA in HeLa and SiHa cells. Flow cytometric analysis revealed a significant increase in the proportion of cells in the G2/M phase in (A) SiHa and (B) HeLa cells in which CCT3 expression was knocked down. Silencing of CCT3 also promoted (C) SiHa and (D) HeLa cell apoptosis. (E) Bcl2 and Bax protein expression levels were downregulated and upregulated, respectively, as detected via western blotting. *P<0.05 and ***P<0.01 vs. control. CCT3, chaperonin containing TCP1 subunit 3; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; sh, short hairpin (RNA); Ctrl, control.
detected in SiHa cells following CCT3-knockdown. The results revealed that the protein levels of p-p38, FN1 and MMP9 were markedly downregulated following CCT3-knockdown (Fig. 7A). Among these proteins, FN1 was selected for further validation as other downstream proteins were unable to rescue CCT3 knockdown-induced cell proliferative inhibition (data not shown). Of note, CCT3 expression was significantly and positively correlated with that of FN1 in CESC (Fig. 7B). A higher expression level of FN1 was also associated with a shorter disease-free survival time in CESC (Fig. 7C and D). These results suggested that FN1 may function as a downstream regulator of CCT3 in human CESC.

Overexpression of FN1 rescues the effects on CESC mediated by CCT3-knockdown. The present study further investigated the association between CCT3 and FN1. Cell viability assays revealed that the overexpression of FN1 significantly reversed the suppressive effects of CCT3-knockdown on the proliferation of both
HeLa and SiHa cells (Fig. 8A-D). Furthermore, the results of the Transwell assays revealed that the overexpression of FN1 significantly reversed the suppressive effects of CCT3-knockdown on the migration of SiHa and HeLa cells (Fig. 8E). Collectively, these data suggested that the regulatory effects of CCT3 on CESC cell functions were mediated via the FN1 gene.

The present study identified that CCT3 expression levels were upregulated in CESC tissues, which was associated with poor patient prognosis. Moreover, the findings revealed that CCT3 suppressed apoptosis and promoted cell cycle progression and metastatic capacity via the FN1 signaling pathway, which demonstrated that CCT3 may prove to be a potential biomarker for CESC.

Discussion

CESC is a major cause of cancer-related mortality among women in China (2). However, the mechanisms regulating the development of CESC remain largely unknown. It is thus imperative to investigate the underlying mechanisms, and to identify promising prognostic indicators, for CESC. The results of the present study revealed that CCT3 expression levels were higher in CESC tissues, and that this was associated with a poor prognosis.

CCT proteins have been demonstrated to play an elementary role in human cancers, including breast cancer and lung cancer, and multiple members of this family have been found to be abnormally expressed, and to be associated with tumor development (7,23-25). For example, CCT2 expression was found to be upregulated in liver (26), colon (10) and lung cancer (27). Higher CCT2 levels are also associated with shorter overall survival times in patients with non-small cell lung cancer (27). CCT8 expression has been revealed to be upregulated in HCC and glioma, and to promote cellular proliferation and migration therein (28). Furthermore, CCT3 expression was found to be upregulated in liver, breast cancer...
and colorectal cancer (22,26,29). To the best of our knowledge, the present study was the first to detect the expression patterns and prognostic value of CCT3 in CESC using TCGA and GEO databases, where CCT3 expression was found to be upregulated in tumor samples compared with normal tissues.

Bioinformatics analysis also confirmed CCT3 as a tumor promoter in CESC cell models. Kaplan-Meier survival and Cox proportional hazards regression analyses indicated that CCT3 expression was associated with the shorter survival time of patients with CESC. Furthermore, in vitro studies indicated that CCT3 promoted the metastatic capacity of tumor cells; CCT3-knockdown significantly reduced the migration and invasiveness of CESC cells. However, when CCT3 was overexpressed, limited increases in CESC cell proliferation and migration were observed. This may be attributed to the fact that high expression of background CCT3 (or exogenous upregulation) in CESC cells is sufficient for promoting cellular proliferation and migration. In previous studies, CCT3 was found to be a regulator of the cell cycle in multiple cancer types (15,22,26). Thus, the present study further validated the potential effects of CCT3-knockdown, demonstrating a marked suppression in CESC cell proliferation and cell cycle progression, and apoptosis promotion. After screening multiple cancer regulators, FN1 expression levels were downregulated

Figure 8. Overexpression of FN1 reverses the effects of CCT3-knockdown on CESC cells. Celigo analysis revealed that the overexpression of FN1 increased the proliferation rate of (A) HeLa and (B) SiHa cells following CCT3-knockdown. MTT assays revealed that the overexpression of FN1 increased the proliferation rate of (C) HeLa and (D) SiHa cells following CCT3-knockdown. (E) Transwell analysis revealed that the overexpression of FN1 increased HeLa and SiHa cell migration rate, following CCT3-knockdown. ***P<0.001 (CCT3 KD + FN1 ND vs. CCT3 NC + FN1 NC); ###P<0.001 (CCT3 KD + FN1 OE vs. CCT3 KD + FN1 OE). CCT3, chaperonin containing TCP1 subunit 3; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; FN1, fibronectin 1; NC, negative control; KD, knockdown.
when CCT3 was inhibited. Moreover, FN1 overexpression rescued the inhibitory effect of CCT3. These data identified that FN1 may be a downstream target of CCT3. To the best of our knowledge, the present study demonstrated for the first time that CCT3 promoted FN1 expression in CESC cells.

FN1 is a member of the FN protein family, is widely expressed in multiple cell types, and plays pivotal roles in cellular adhesion and migration processes (30). Previous research has demonstrated that higher expression levels of FN1 are associated with advanced tumor stage (31). FN1 has been reported to be involved in tumor metastasis and extracellular matrix-related changes, such as the epithelial-mesenchymal transition (32). The downregulation of FN1 has also been shown to suppress colorectal tumorigenesis by regulating proliferation, migration and invasion (33), and emerging evidence has indicated that FN1 is an important regulator of tumor cell chemoresistance (34). In addition, mechanistic analyses have suggested that FN1 may interact with vascular endothelial growth factor A, and play a primary role in non-small cell lung cancer (35). Moreover, FN1 was reported to promote Src and caspase-8 phosphorylation in lung cancer cells. The present study identified multiple proliferation, migration and cell cycle regulators in SiHa cells following CCT3-knockdown, including CDH1, CDH2, p-p38, FN1, MMP9, TWIST, MMP9, mTOR, MYC, NF-κB-p65, p-mTOR, VIM, p-NF-κB-p65, p-β-catenin, p38 and β-catenin. FN1 protein levels were suppressed following CCT3-knockdown in CESC cells, and thus, FN1 may be a downstream target of CCT3. FN1 was subsequently selected for further validation. However, this does not mean that there are no other proteins of research value in this context, such as p53, retinoblastoma or PTEN (36,37). Furthermore, cell viability and Transwell assays revealed that the overexpression of FN1 significantly reversed the suppressive effects of CCT3-knockdown on the proliferation and migration of HeLa and SiHa cells. Collectively, these data suggest that CCT3 induced its effects on cellular functions via regulation of the FN1 gene.

In conclusion, the results of the present study indicated that CCT3 acts as an oncogene in CESC, and was found to be associated with a poor patient prognosis. The data also indicated that CCT3 promoted cellular invasion and migration ability. Moreover, CCT3 was found to be involved in regulating FN1 gene expression, thus regulating cell cycle and migration progression. Collectively, the data indicate that CCT3 may be regarded as a prognostic indicator of CESC, and may prove to be a novel target for the treatment of CESC.

Acknowledgements

Not applicable.

Funding

The present study was supported by internal funding from The First Hospital of China Medical University (Shenyang, China).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LD designed the experiments and wrote the paper. XZ performed the experiments and participated in study design and writing. Both authors have read and approved the manuscript. LD and XZ confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.